Crohn’s disease (CD) is a chronic debilitating illness with limited effective treatment options, especially for patients with moderate to severe disease. Treatment options for CD include conventional, largely generic small molecules and more-potent biologics. Despite the clinical and commercial success of the tumor-necrosis factor-alpha (TNF-α) inhibitors, opportunity remains for agents that can safely and effectively induce and maintain remission in greater numbers of patients with moderate to severe CD. Indeed, the cell adhesion molecule (CAM) inhibitor vedolizumab (Takeda’s Entyvio) is an option for adult patients with moderate to severe CD who have failed conventional therapies and/or TNF-α inhibitors. The interleukin (IL)-12/IL-23 inhibitor ustekinumab (Janssen’s Stelara), which was recently approved in the United States and received a positive opinion in Europe, is expected to launch in both regions for CD during the 2015-2025 study period. Other promising agents in late-stage development that are geared toward the moderate to severe CD population include Roche’s CAM inhibitor etrolizumab, Galapagos’s JAK inhibitor filgotinib, and the oral SMAD7 antisense oligonucleotide mongersen (Celgene’s GED-0301). This Disease Landscape and Forecast provides a detailed analysis of these late-phase pipeline candidates and an annualized ten-year forecast for the CD therapy market (2015-2025) in the seven major pharmaceutical markets under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). Detailed, updated epidemiological estimates and in-depth coverage of the current treatment landscape are also included.